Chronic kidney disease is a progressive disease with no cure and high morbidity and
mortality that occurs commonly in the general adult population, especially in people with …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Executive summary 2020 will go down in history as the year when the global community was
awakened to the fragility of human health and the interdependence of the ecosystem …

The American Diabetes Association and the European Association for the Study of Diabetes
have briefly updated their 2018 recommendations on management of hyperglycemia, based …

Summary Background The DiRECT trial assessed remission of type 2 diabetes during a
primary care-led weight-management programme. At 1 year, 68 (46%) of 149 intervention …

Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the
mechanisms underlying the plasma glucose level-lowering effects of metformin (1, 1 …

Objective To provide evidence-based recommendations regarding the use of advanced
technology in the management of persons with diabetes mellitus to clinicians, diabetes-care …

Dipeptidyl peptidase 4 inhibitors (DPP4i) have been available for treating type 2 diabetes
mellitus since 2006. Although they are a diverse group, DPP4i are all small, orally available …

The remarkable advancements in biotechnology and public healthcare infrastructures have
led to a momentous production of critical and sensitive healthcare data. By applying …

Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective
treatments for type 2 diabetes, lowering glycated haemoglobin (HbA 1c) and weight, but are …